Sucampo Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Mizuho Securities Reiterates Buy on Sucampo Pharma (SCMP) as Amitiza Royalies Drives 2Q Beat
August 3, 2016 9:12 AM EDTMizuho Securities reiterated a Buy rating and $14.00 price target on Sucampo Pharmaceuticals (NASDAQ: SCMP) following the company's 2Q earnings report. SCMP reported revenues of $52.0M and $0.23 in EPS vs. consensus of $48.6M and $0.22. The beat was driven primarily by higher royalty revenue from Amitiza... More
Sucampo Pharma (SCMP) Tops Q2 EPS by 1c
August 3, 2016 8:09 AM EDTSucampo Pharma (NASDAQ: SCMP) reported Q2 EPS of $0.23, $0.01 better than the analyst estimate of $0.22. Revenue for the quarter came in at $52 million versus the consensus estimate of $48.61 million.
For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.
... More